[JAMA Article] New Oncology Drugs Command High Price Tags Despite Lack of Improved Survival

In an article published in JAMA Internal Medicine, researchers assessed the costs of 44 new oncology drugs. Surprisingly, they found that an increasing number of patients were receiving drugs without clear overall survival data.

“The investigators suggested that the increased spending on cancer drugs without overall survival data is a result of several factors, including: increasingly lenient FDA approvals, drugs advertised directly to consumers, no price regulation, fragmented purchasing and reimbursement systems, coverage mandates, and limited ability by payers to negotiate prices.” Read more here.

(Source: Denise Myshko, Formulary Watch, 10/25/21)